Antimicrobial Agents and Chemotherapy, April 2007, p. 1563-1565, Vol. 51, No. 4
0066-4804/07/$08.00+0 doi:10.1128/AAC.01326-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs
Boris V. Nikonenko,1,2*
Marina Protopopova,1
Rowena Samala,1
Leo Einck,1 and
Carol A. Nacy1
Sequella, Inc., Rockville, Maryland 20850,1
Central Research Institute for Tuberculosis, Moscow 107564, Russia2
Received 24 October 2006/
Returned for modification 27 November 2006/
Accepted 13 January 2007
Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log10 lower in SQ109-containing regimens.
* Corresponding author. Mailing address: Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850. Phone: (301) 762-7776. Fax: (301) 762-7778. E-mail: borisnikonenko{at}sequella.com
Published ahead of print on 22 January 2007.
Antimicrobial Agents and Chemotherapy, April 2007, p. 1563-1565, Vol. 51, No. 4
0066-4804/07/$08.00+0 doi:10.1128/AAC.01326-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Copyright © 2007 by the American Society for Microbiology. All rights reserved.